INmune Bio, Inc.
XPro
Alzheimer’s disease
Resolved
372days ago
Phase 2 readout · Jun 30, 2025
What's at stake
Phase 2 trial results for XPro in Alzheimer’s disease are due Jun 30, 2025. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 12h ago
“INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease”